Contribute Try STAT+ Today

Since the controversial approval of the Alzheimer’s drug Aduhelm, both the Food and Drug Administration and the drug’s maker, Biogen, have made an interesting argument: that approving the medicine will speed the development of other Alzheimer’s treatments, whatever one thinks of this medicine’s efficacy.

“If we look at the past experience, progress has to be made with the first step, and we can look at HIV, oncology, or [multiple sclerosis],” Biogen’s CEO, Michel Vounatsos, said on the company’s earnings call last week. His remarks echoed those of Patrizia Cavazzoni, who heads the FDA center that regulates new medicines.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment